Accelerant Holdings (ARX) Stock Price & How to Invest
Last updated November 2026
Short answer
Accelerant Holdings (ARX) has agreed to be taken private by affiliates of private-equity firm Thoma Bravo for $20.25 per share in cash, a deal announced August 13, 2026 that values the company at an enterprise value of more than $4 billion. Until it closes (expected in the first half of 2027, subject to a shareholder vote and regulatory approvals), ARX still trades on the NYSE and can be bought like any stock, but its price now tracks the deal: it closed at $19.75 on October 16, 2026, about 2.5% below the offer. Accelerant runs a technology-driven risk exchange that connects specialty insurance underwriters (managing general agents, or MGAs) with the capital partners who fund their risk, earning fee-based revenue rather than carrying most of the underwriting risk itself.
ARX stock price
As of 2026-11-16, Accelerant Holdings (ARX) last closed at $19.87, up 53.7% over the past year. Over the past 52 weeks it has traded between $9.36 and $19.91.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Accelerant Holdings's investor relations page. Walnut is informational, not investment advice.
ARX key stats
At $19.87 on November 16, 2026, Accelerant Holdings (ARX) has a market cap of $4.3B.
- Market cap
- $4.3B
- P/E (forward)
- 21.2
- Price to book
- 6.0
Market cap, P/E and yield are measured at the $19.87 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Accelerant Holdings (ARX)?
The last two weeks for Accelerant Holdings, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- ARX closed at $19.87 on November 16, 2026, down 0.1% over the past five trading days (from $19.88).
- On November 12, 2026, Accelerant Holdings filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 12, 2026, Accelerant Holdings filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Accelerant Holdings (ARX) do?
Accelerant Holdings operates a data-driven risk exchange for specialty insurance. On one side are managing general agents (MGAs), the specialist underwriters who design and sell niche insurance products; on the other are risk capital partners such as insurers, reinsurers, and institutional investors who put up the capital to back those policies. Accelerant sits in the middle, using proprietary technology, data, and machine learning to match risk with capital, share high-fidelity underwriting data, and monitor portfolios. It earns a fixed-percentage, volume-based fee for sourcing, managing, and monitoring the business written through the exchange, which spans more than 500 specialty insurance products across 22 countries. The company reports through three segments: Exchange Services, MGA Operations, and Underwriting, and describes its model as capital-light because it aims to retain only a small share of the premium risk (roughly 9% in 2025) and pass the rest to third-party capital.
The defining fact for the stock is now the pending sale. On August 13, 2026 Accelerant agreed to be acquired by affiliates of Thoma Bravo (through entities named Cherry Tree BidCo and Cherry Tree Merger Sub) in an all-cash deal at $20.25 per share, an enterprise value of more than $4 billion. The shares jumped about 43% on the announcement day. The agreement included a 40-day go-shop that let Accelerant solicit better offers; it expired on September 22, 2026 with no alternative proposal from any third party. Closing is expected in the first half of 2027, subject to approval by Accelerant shareholders at a special meeting, required regulatory approvals and other customary conditions. When it completes, ARX holders receive $20.25 in cash per share and the stock is delisted from the NYSE. As of October 16, 2026 the shares closed at $19.75, up about 26% year to date and 50% over the past year, for a market cap near $4.3 billion.
The operating business was growing quickly going into the deal. In 2025 the exchange handled about $4.19 billion of Exchange Written Premium, up roughly 35% year over year, with revenue rising about 51% to $913 million and adjusted EBITDA up sharply to $282 million; the headline $1.35 billion net loss stemmed almost entirely from a $1.38 billion non-cash profits interest distribution tied to the July 2025 IPO, which raised about $724 million. In Q2 2026 revenue rose about 57% year over year to roughly $357 million, net income was about $79 million, and adjusted EPS of $0.32 doubled the $0.16 estimate. Those results now matter mainly as context for the price Thoma Bravo agreed to pay.
What's driving Accelerant Holdings (ARX)?
1. The Thoma Bravo deal sets the price
Thoma Bravo's affiliates have agreed to pay $20.25 per share in cash. With the stock at $19.75 on October 16, 2026, the market is pricing a high probability of completion, leaving a spread of about 50 cents, or roughly 2.5%, for holders who wait until closing. As long as the deal stays on track, the share price is likely to move with the perceived odds of closing and the time to close rather than with Accelerant's quarterly results.
2. Go-shop ended with no rival bid
The merger agreement gave Accelerant 40 days to solicit competing offers. That window expired on September 22, 2026 and the company said it received no alternative acquisition proposals. A higher bid can still emerge in principle, but the quiet go-shop makes $20.25 the working assumption for what holders receive.
3. Remaining steps to close
The transaction still needs approval from Accelerant shareholders at a special meeting (the company plans a proxy statement), required regulatory approvals for an insurance-related business, and other customary conditions, with a Schedule 13E-3 filed if required. Management expects completion in the first half of 2027, after which the shares will stop trading on the NYSE.
4. The business behind the bid
Growth was strong when the deal was struck: Q2 2026 revenue rose about 57% year over year to about $357 million, net income was about $79 million, and adjusted EPS of $0.32 doubled estimates. Accelerant had been adding MGA members and capital partners, steering more premium to third-party capital (it retained about 9% in 2025), and showing operating leverage. These fundamentals matter now chiefly as a fallback: if the deal broke, they would be what the stock trades on again.
What are the risks to Accelerant Holdings (ARX)?
With a signed all-cash agreement, the main risk is deal completion. Shareholder approval, regulatory approvals for an insurance business, financing and other conditions could delay or block the transaction, and the expected close in the first half of 2027 leaves months for something to change. If the deal failed, the stock would likely fall back toward a price set by fundamentals; it traded near $13 in July 2026, before the announcement-day jump of about 43%. The upside is capped near $20.25 unless a higher bid appears, and the go-shop ended without one. Holders also bear the time value of waiting: a roughly 2.5% spread over several months is a modest return for that risk. The underlying business risks still apply to a broken-deal scenario: a capital-light model unproven across a full insurance cycle, dependence on keeping MGAs and capital partners engaged, a large reported net loss tied to the IPO, and cyclical specialty insurance pricing.
What is the Accelerant Holdings (ARX) forecast?
3 analysts publish price targets on ARX, averaging $20.25 as of November 2026, or +1.9% against the $19.87 share price on November 16, 2026. The published targets run from $20.25 to $20.25, a narrow spread, and the ratings split 0 buy, 5 hold, 1 sell. Over the last six months there have been 3 raises and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full ARX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is ARX a buy or a sell?
We give no verdict on Accelerant Holdings. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. The Thoma Bravo deal sets the price. Thoma Bravo's affiliates have agreed to pay $20.25 per share in cash. The most optimistic published target, $20.25, assumes this works close to its best case.
The case against. With a signed all-cash agreement, the main risk is deal completion. The most pessimistic target, $20.25, is roughly what ARX is worth if this bites instead.
Read the full bull and bear case on ARX, including what would have to change to break either one. Walnut is not an investment adviser.
Has Accelerant Holdings (ARX) split its stock?
No. Accelerant Holdings (ARX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Accelerant Holdings (ARX) valued?
Market cap, P/E and dividend yield at today's price are in the ARX key stats above. The business figures below come from Accelerant Holdings's reported results as of October 2026 and change when it next reports.
- Deal price (Thoma Bravo, all cash): $20.25 per share; enterprise value >$4 billion
- Expected close: First half of 2027
- Revenue (TTM): ~$1.07 billion
- Q2 2026 revenue: ~$357 million (up ~57% YoY)
- Net income (TTM): ~-$1.37 billion (mostly the non-cash IPO item)
As of October 2026: Since August 13, 2026 ARX has been valued by the Thoma Bravo offer, not by earnings multiples. At $19.75 the shares trade about 2.5% below the $20.25 cash price, a spread that reflects the time until the expected first-half 2027 close and the chance the deal does not complete. Measures such as about 4 times TTM sales or 21 times forward earnings describe what the buyer is paying rather than where the stock is likely to trade before closing.
Who competes with Accelerant Holdings (ARX)?
Specialty insurance distributors and marketplaces
Companies that connect specialty underwriters with markets and capital, such as Ryan Specialty Holdings and Goosehead Insurance, overlap with parts of Accelerant's distribution and MGA-facing role. They compete for the same MGA relationships and specialty premium flow, though their exact models differ from Accelerant's data-driven exchange.
Fronting carriers and hybrid MGA-capital platforms
Fronting insurers and program carriers (including players like Trisura and other program-focused specialty carriers) offer MGAs a way to access paper and capital. They are the most direct alternative to routing business through Accelerant's exchange, competing on fees, capital access, and speed.
Traditional insurers and reinsurers
Established carriers and reinsurers can back specialty programs directly or build their own MGA and program units, keeping premium off third-party platforms. Their scale and balance-sheet capacity make them both potential capital partners on Accelerant's exchange and competitors for the same specialty risk.
What stocks are similar to Accelerant Holdings (ARX)?
Other names that sit close to ARX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Accelerant Holdings (ARX)
There are three common ways to get ARX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so ARX sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where ARX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Accelerant Holdings (ARX)
ARX is now a merger-arbitrage situation rather than an open-ended growth story. Thoma Bravo has agreed to pay $20.25 in cash for each share, a 40-day go-shop ended September 22, 2026 without a competing proposal, and the shares at $19.75 sit just under the offer price. The remaining upside for a holder is the gap to $20.25, and the main risk is that the deal fails to close, in which case the stock would again trade on the fundamentals of a fast-growing, fee-based insurance marketplace.
More on Accelerant Holdings (ARX)
Whether ARX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ARX a buy or a sell?, and where the stock could go from here in the ARX stock forecast.
For income investors, whether ARX pays a dividend and how the payout looks is covered in does ARX pay a dividend? And to weigh ARX against a peer, read the full side-by-side comparisons: ARX vs RYAN and ARX vs GSHD.
Wondering how ARX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Accelerant Holdings
Ask Walnut's AI anything about ARX and see how it fits what you own.
FAQ
What does Accelerant Holdings (ARX) do?
+
Accelerant runs a technology-driven risk exchange for specialty insurance. It connects managing general agents (MGAs), the specialists who design and sell niche insurance products, with risk capital partners such as insurers, reinsurers, and institutional investors who fund the policies. Accelerant uses data and machine learning to match risk with capital and earns a volume-based fee on the premium that flows through its platform, across more than 500 products in 22 countries. In August 2026 it agreed to be acquired by affiliates of Thoma Bravo for $20.25 per share in cash.
Is ARX a good stock to buy right now?
+
That depends on your goals, and this is not investment advice. Since the August 13, 2026 agreement with Thoma Bravo, ARX mostly offers a merger-arbitrage profile: at $19.75 (October 16, 2026) the shares sit about 2.5% below the $20.25 cash price, which holders receive if the deal closes as expected in the first half of 2027. The risk is that the deal is delayed or fails, in which case the stock would trade on the fundamentals of a young, fast-growing but unproven insurance marketplace. Weigh both against your own portfolio.
When did Accelerant Holdings go public?
+
Accelerant listed its Class A common shares on the New York Stock Exchange under the ticker ARX on July 24, 2025, raising roughly $724 million in the IPO. Its life as a public company is set to be short: in August 2026 it agreed to be taken private by Thoma Bravo, and the shares will be delisted when that deal closes, expected in the first half of 2027.
Why did Accelerant report a $1.35 billion loss in 2025?
+
The 2025 net loss of about $1.35 billion came almost entirely from a roughly $1.38 billion non-cash profits interest distribution tied to the IPO, not from ongoing operations. On an operating basis the company grew adjusted EBITDA to about $282 million. The gap between the reported loss and adjusted metrics is why it helps to look at both figures rather than the headline number alone.
How does Accelerant make money?
+
Accelerant primarily earns fee-based revenue. Risk capital partners write premium through its exchange and pay a fixed-percentage, volume-based fee for Accelerant sourcing, managing, and monitoring that business. It also has MGA Operations and Underwriting segments. Because it aims to retain only a small share of the premium risk (around 9% in 2025) and pass the rest to third-party capital, its model is described as capital-light.
What does 'capital-light' mean for Accelerant?
+
Capital-light means Accelerant tries to keep only a small portion of the insurance risk on its own balance sheet and route most premium to outside capital partners. That makes its revenue more fee-like and, in theory, less exposed to large underwriting losses, while freeing up surplus capital. The trade-off is that the business depends on continually attracting and retaining those third-party capital providers.
Who are Accelerant's main competitors?
+
Accelerant competes with specialty insurance distributors and marketplaces such as Ryan Specialty and Goosehead Insurance, with fronting carriers and program specialists like Trisura that give MGAs access to paper and capital, and with traditional insurers and reinsurers that can back specialty programs directly. Each offers MGAs a different route to capital, so competition centers on fees, data, and capital access.
Does ARX pay a dividend?
+
Accelerant does not pay a regular dividend. As a recently public, fast-growing company it reinvested in its exchange, technology and international footprint, and under the pending Thoma Bravo deal the return for holders is the $20.25 per share cash payment at closing rather than income.
Is Accelerant being acquired?
+
Yes. On August 13, 2026 Accelerant agreed to be acquired by affiliates of Thoma Bravo in an all-cash transaction at $20.25 per share, an enterprise value of more than $4 billion. A 40-day go-shop expired on September 22, 2026 with no competing proposal. Closing is expected in the first half of 2027, subject to shareholder and regulatory approvals, after which ARX will stop trading on the NYSE.
How did Accelerant do in its latest quarter?
+
In Q2 2026 Accelerant reported revenue of about $357 million, up roughly 57% year over year, and net income of about $79 million. Adjusted EPS of $0.32 was double the $0.16 consensus. With the Thoma Bravo deal pending, quarterly results now have much less effect on the share price than progress toward closing.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Accelerant Holdings's investor relations page or your broker before making investment decisions.